Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKesson
Express Scripts
Merck
McKinsey

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR STROMECTOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Stromectol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00921154 ↗ Ivermectin Solution Bioequivalence Study - Fasted Completed Johnson & Johnson Consumer and Personal Products Worldwide Phase 1 2005-03-01 The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of ivermectin solution 1 mg/ml with a marketed reference formulation of ivermectin 3 mg tablets when taken after an overnight fast .The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001.
NCT00921219 ↗ Ivermectin Solution Bioequivalence Study - With Food (Repeat) Completed Johnson & Johnson Consumer and Personal Products Worldwide Phase 1 2005-09-01 The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of Ivermectin solution 1 mg/ml with a marketed reference formulation of Ivermectin 3 mg tablets when taken after a standard meal. The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001.
NCT00921674 ↗ Ivermectin Solution Bioequivalence Study - With Food Completed Johnson & Johnson Consumer and Personal Products Worldwide Phase 1 2005-02-01 The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of Ivermectin solution 1 mg/ml with a marketed reference formulation of Ivermectin 3 mg tablets when taken after a standard meal. The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001.
NCT01570504 ↗ Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis Completed European Commission Phase 3 2013-03-01 Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite. Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.
NCT01570504 ↗ Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis Completed Centro per le Malattie Tropicali Phase 3 2013-03-01 Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite. Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.
NCT02045069 ↗ Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status Ministry of Health, Thailand Phase 2/Phase 3 2014-02-01 This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Stromectol

Condition Name

Condition Name for Stromectol
Intervention Trials
Healthy 4
Strongyloidiasis 2
Malaria 2
Onchocerciasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Stromectol
Intervention Trials
Infections 3
Communicable Diseases 3
COVID-19 3
Malaria 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Stromectol

Trials by Country

Trials by Country for Stromectol
Location Trials
United States 10
Spain 3
Italy 2
United Kingdom 2
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Stromectol
Location Trials
California 3
Minnesota 1
Indiana 1
Illinois 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Stromectol

Clinical Trial Phase

Clinical Trial Phase for Stromectol
Clinical Trial Phase Trials
Phase 3 6
Phase 2/Phase 3 1
Phase 2 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Stromectol
Clinical Trial Phase Trials
Completed 10
Recruiting 4
Withdrawn 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Stromectol

Sponsor Name

Sponsor Name for Stromectol
Sponsor Trials
Johnson & Johnson Consumer and Personal Products Worldwide 3
Barcelona Institute for Global Health 2
Northwestern University 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Stromectol
Sponsor Trials
Other 26
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Colorcon
Harvard Business School
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.